tubules into the surrounding interstitium and peritubular capillaries. 6 Though BK nephropathy occurs infrequently in patients following other solid organ transplant or bone marrow transplant, it is much more common after kidney transplantation. 1, 7 Coincident with the adoption of increasingly aggressive immunosuppressive regimens, the incidence and prevalence of BK nephropathy has increased in recent years compared to when the condition was first described in the mid-1990s. 2 Higher-potency immunosuppression regimens are thought to create a permissive environment for BK viral replication and represent an important risk factor for viral reactivation.
In addition to the overall degree of immunosuppression, certain agents have been associated with higher risk of BK nephropathy in studies, including rabbit antithymocyte globulin induction. 8, 9 and maintenance immunosuppression with tacrolimus and mycophenolate. 1, 2, 7, 9, 10 Corticosteroid maintenance therapy has also been associated with increased risk of BK viremia or nephropathy in limited studies. 2, [8] [9] [10] Management of BK nephropathy predominantly involves reduction of immunosuppression as anti-BK effective therapies are limited. 4 Risk factors for BK virus reactivation are incompletely understood, though a myriad of risk factors have been posited including characteristics pertaining to the graft, recipient, and type of immunosuppression regimen. Graft-related risk factors include ischemic allograft injury, prior acute rejection, degree of HLA mismatch, high BK-specific antibody titers, and BK serologic mismatch (seropositive donor and seronegative recipient), though serologic status is not routinely clinically assessed. 2, 11, 12 Recipient-related risk factors for BK reactivation include older age, Caucasian ethnicity, and male sex. 8, 13 It is currently unknown whether the cause of ESRD affects BK viral reactivation or nephropathy. We hypothesized that patients with exposure to pretransplant immunosuppression (patients with glomerulonephritis, GN) or relatively immunosuppressed patients (patients with diabetes mellitus, DM), would be more susceptible to the development of BK viremia and nephropathy in the post-transplant period. We sought to better characterize the risk of BK viremia and nephropathy in transplant recipients by comparing incidence of BK viremia and nephropathy by cause of ESRD. Better understanding of risk factors for BK reactivation and nephropathy could allow for identification of at-risk populations, improve predictive models and surveillance strategies, and potentially allow for optimization of risk factors and management of disease.
| ME THODS

| Patient population
Patients eligible for inclusion in this study consisted of all consecutive adult (>18 years old) renal transplant recipients at the University 
| Protocol for BK laboratory monitoring and immunosuppression medication adjustment
The protocol for laboratory monitoring of BK viremia and adjustment of immunosuppression at our center was performed as previously described. 3, 12 Briefly, plasma BK PCR was monitored every 2 weeks for the first 3 months post-transplant, then monthly until 6 months post-transplant, and then every 3 months until 18 months post-transplant. Allograft biopsy was performed if BK PCR was positive and/or creatinine was elevated 25% above baseline. If the BK PCR level was greater than 1,000 copies/mL, the anti-metabolite dose was reduced by 50%, followed by a reduction in calcineurin inhibitor dose. If BK PCR level continued to increase, the anti-metabolite was replaced with leflunomide ± intravenous immunoglobulin. If a diagnosis of acute rejection was determined on allograft biopsy, BK PCR was monitored every 2 weeks for 3 months.
| Statistical analysis
Continuous variables were compared between groups using t tests and Kruskal-Wallis tests. Categorical variables were compared between groups with chi-square or Fisher exact tests. Time-toevent data estimates were obtained using Kaplan-Meier curves and log-rank test. Cox proportional hazard models were used to assess independent associations between demographics, baseline characteristics, BK viremia, and BK nephropathy. P value less than 0.05 were considered statistically significant. All analyses were performed using Stata Statistical Software: Release 13 (StataCorp;
College Station, TX, USA). were no significant differences in induction immunosuppression regimens between the four groups. Maintenance immunosuppression regimens at time of discharge were also similar among the groups, with the exception of a higher percentage of patients in the PKD group receiving mycophenolate for maintenance immunosuppression. HLA mismatch >2 was more common among the HTN and PKD groups. Delayed graft failure occurred at a significantly higher rate in the HTN and DM groups, but did not significantly differ between GN and PKD.
| RE SULTS
| Baseline characteristics
| Risk of BK viremia is lower in PKD compared with other causes of ESRD
Out of a total of 2,741 kidney transplant patients, 327 (12%) developed BK viremia over a median follow-up time of 5.1 years (Table 2 ).
There were no significant differences in the incidence of acute rejection among the four groups (GN: 4.2 per 100 person-years, HTN: 
| Risk of BK nephropathy was lower in patients with PKD compared to HTN or DM
A total of 77 patients developed BK nephropathy. The lowest proportion of patients with BK nephropathy was observed in the PKD group, compared to other causes of ESRD (P = 0.003
for PKD vs HTN, P = 0.19 for PKD vs GN, P = 0.04 for PKD vs DM), as shown in Figure 1B . The incidence rate of BK nephropathy was significantly lower in PKD compared to DM and HTN groups (P = 0.02 and P = 0.001, respectively, 
| PKD patients who underwent nephrectomy had a lower risk of BK viremia compared to those without nephrectomy
A total of 549 study patients received kidney transplants for ESRD due to PKD. Of these patients, 280 underwent surgical nephrectomy prior to diagnosis of BK viremia, and 269 did not undergo nephrectomy (Table 4) Our findings suggest a potential protective effect of PKD anatomy or physiology against post-transplant BK viremia and nephropathy, and are concordant with the findings of Mitterhofer et al. 21 In this study of 47 renal transplant patients, a lower rate of BK viremia was observed among PKD patients compared to non-PKD patients at 12 hours, 3 months, and 6 months after transplantation. This difference is posited to be attributable to lower cellular permissivity of the renal tubular epithelial cells in PKD to BK viral replication; these cells in PKD are characteristically non-differentiated but remain capable of proliferating. 21 In the majority of cases of PKD, mutations in the genes PKD1 or PKD2 lead to abnormalities in transmembrane proteins (polycystin 1 and polycystin 2), responsible for multiple cellular functions including maintenance of renal tubule cell differentiation. A study by Atencio and Villarreal lent support to the theory that BK virus infectivity is hindered by lack of renal tubule cell differentiation in PKD. 22 Employing an adult mouse model of PKD, they demonstrated that tubule cell proliferation alone was not sufficient to permit polyomavirus infection, and proposed that terminal differentiation of the host cell is also required for BK infectivity. 
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